Metraipolis › archive › dc_8b4a8aace93a

Azoximer bromide — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/Azoximer_bromide
License (as archived)
CC-BY-SA-4.0
Archived
2026-11-10T15:54:42.873Z
SHA-256 of the archived text
e80b17639138d0d7f707b145749f9a384c5dcb5d8de24e25fe38618c42684bf2
Stable URL of this page
https://metraipolis.com/documento/dc_8b4a8aace93a

How to cite

Azoximer bromide — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Azoximer_bromide (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_8b4a8aace93a (Metraipolis archive dc_8b4a8aace93a, sha256 e80b17639138d0d7f707b145749f9a384c5dcb5d8de24e25fe38618c42684bf2)
BibTeX
@misc{dc8b4a8aace93a,
  title = {Azoximer bromide — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Azoximer_bromide},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_8b4a8aace93a; sha256 e80b17639138d0d7f707b145749f9a384c5dcb5d8de24e25fe38618c42684bf2},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Azoximer_bromide. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Azoximer bromide, sold by the trade name Polyoxidonium by Petrovax NPO, is a water-soluble cationic polymer, adjuvant for use with the hemagglutinin glycoprotein-based influenza vaccine Grippol. Azoximer bromide is a ternary copolymer of 1,4-ethylene piperazine, 1,4-ethylene piperazine-N-oxide, and (N-carboxymethylene)-1,4-ethylene piperazinium bromide with a molecular weight of 60–100 kDa. A derivative of poly(1,4-ethylene piperazine), it is synthesized by a partial oxidation of the parent polymer with hydrogen peroxide to introduce N-oxide groups followed by the quaternization of non-oxidized amino groups with bromoacetic acid. Azoximer bromide is registered under US Patent-5503830 from 1996, and in the Russian Federation from 1996, under registration number 96/302/9, FS 42-3906-00. In Slovakia, azoximer bromide 6 mg lyophilisate for solution for injection has been authorized since 2002 for the treatment of diseases accompanied by secondary immunodeficiency in adults, including acute and recurrent infections, allergies, septic conditions, post-surgical complications and treatment-induced immune deficiency. The clinical effectiveness of azoximer bromide has not been confirmed by independent clinical studies that meet modern standards of evidence-based medicine: there are few double-blind randomized and placebo-controlled studies with a sufficient number of participants and the publication of results in well-regarded scientific journals with high impact factors.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «Azoximer bromide» — https://en.wikipedia.org/wiki/Azoximer_bromide
Wikidata Q4058443: «composto chimico» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q4058443
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Azoximer_bromide?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1336812032, consultata il 2026-11-10T15:44:02.029Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: e56a734866be7366af75fd0201311372781b990b2356594a3beb1410143f70f9